A cholesterol drug made by Merck that is not a statin met the primary goal of a late-stage clinical trial, the New Jersey-based company and researchers it works with said on March 30.
The oral drug, known as enlicitide, reduced low-density lipoprotein cholesterol (LDL-C) among people who took it, compared with arms that took available oral non-statin therapies such as bempedoic acid, according to trial results published in the Journal of the American College of Cardiology. Each arm also took statins.
